Traumatic brain injury (TBI) is seen by the insurance industry and many health care
providers as an “event.” Once treated and provided with a brief period of rehabilitation, the …

Alzheimer's disease is one of the most common causes of mental deterioration in elderly
people, accounting for around 50%-60% of the overall cases of dementia among persons …

Alzheimer's disease is an irreversible, progressive neurodegenerative disorder. Various
therapeutic approaches are being used to improve the cholinergic neurotransmission, but …

This review describes the preclinical mechanisms that may underlie the increased
therapeutic benefit of combination therapy—with the N-methyl-d-aspartate receptor …

Since the finding by Johnson and Ascher (1987) demonstrating that glycine enhances
electrophysiological responses mediated by N-methyl-D-aspartate (NMDA) b

Objectives To assess clinical efficacy and safety of memantine—an uncompetitive N‐methyl‐
d‐aspartate (NMDA) antagonist—in moderately severe to severe primary dementia …

There is increasing evidence for the involvement of glutamate‐mediated neurotoxicity in the
pathogenesis of Alzheimer's disease (AD). We suggest that glutamate receptors of the N …

Recent evidence suggests that neurotrophic factors that promote the survival or
differentiation of developing neurons may also protect mature neurons from neuronal …

Evidence exists for both cholinergic and glutamatergic involvement in the etiology of
Alzheimer's disease. Acetylcholine (ACh), a neurotransmitter essential for processing …

The deficiency in cholinergic neurotransmission in Alzheimer's disease has led to the
development of cholinesterase inhibitors as the first-line treatment for symptoms of this …